Loading…
Employees: 19
Size Arbutus Biopharma (ABUS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $724M, the 2455th largest of 3,117 United States companies the cockpit tracks. Shares closed at $3.65 on 6 Nov 2026.
Performance Over six months the shares fell 15.8%, against -8.9% for the median peer and -1.1% for the United States market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 1,078.8% over the last twelve months (peer median +10.9%); the operating margin is 81.1% (peer median 11.5%).
Valuation It trades at 3.5× enterprise value to sales against a peer median of 3.0× (7th most expensive of 17).
Capital Return on invested capital runs 59.6 points above its cost of capital (9.0% WACC).
Short interest Short interest is 12.4% of the free float (15 Oct 2026).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $182M | $14.1M | $6.17M | $18.1M | $39.0M |
| Revenue growth | — | +128% | -66% | -54% | — |
| Gross profit | $182M | $13.7M | $4.79M | $16.7M | $37.6M |
| EBITDA | $147M | -$26.7M | -$68.6M | -$76.6M | -$61.8M |
| Net income | $153M | -$33.5M | -$69.9M | -$72.8M | -$69.5M |
| Free cash flow | n/a | -$39.6M | -$65.0M | -$86.9M | -$35.9M |
| Capital expenditure | $0 | $0 | $182,000 | $1.01M | $512,000 |
| Total debt | $3.62M | $4.19M | $6.12M | $8.72M | $12.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ABUS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.6% | -6.5% | 7th lowest of 21 |
| 6-month return | -15.8% | -8.9% | 10th lowest of 21 |
| Distance from 52-week high | -32.9% | -29.4% | 10th lowest of 21 |
| Revenue growth (TTM) | +1,078.8% | +10.9% | highest of 17 |
| Operating margin | 81.1% | 11.5% | highest of 16 |
| EV / Sales | 3.5× | 3.0× | 7th most expensive of 17 |
| ROIC minus cost of capital | +59.6 pp | -0.0 pp | 3rd highest of 15 |
| EV / EBITDA | 4.3× | 7.0× | 2nd cheapest of 7 |
| Net debt / EBITDA | -0.6× | -1.1× | 2nd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Arbutus Biopharma ABUS | United States | $724M | -16% | +1,079% | 81% | 3.5× | n/a | n/a |
| Ardelyx ARDX | United States | $724M | -58% | +18% | -8% | 1.5× | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $725M | +4% | +26% | 61% | 2.7× | n/a | n/a |
| Cullinan Therapeutics CGEM | United States | $728M | -22% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $716M | -24% | +5% | -30% | 8.7× | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $711M | -3% | -3% | 16% | 1.7× | -7.5% | -2.8% |
| Hainan Haiyao 000566.SZ | China | $710M | -19% | -18% | -50% | 11.2× | n/a | n/a |
| Rigel Pharmaceuticals RIGL | United States | $741M | +52% | +3% | 31% | 2.5× | -1.1% | +22.1% |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $743M | -32% | +7% | 8% | 7.3× | 33.8% | +19.8% |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $705M | -29% | -82% | n/a | 27.3× | 10.5% | -25.1% |
| Bliss GVS Pharma BLISSGVS.NS | India | $698M | +126% | +21% | 15% | 6.6× | 37.0% | +10.1% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $753M | -11% | +4% | 2% | 0.6× | 4.9% | +5.3% |
| Philogen PHIL.MI | Italy | $694M | -7% | +295% | 79% | 0.9× | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $693M | +28% | n/a | n/a | n/a | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $692M | -16% | +23% | 11% | 3.2× | 10.3% | +7.9% |
| Achieve Life Sciences ACHV | United States | $692M | +29% | n/a | n/a | n/a | n/a | n/a |
| Zevra Therapeutics ZVRA | United States | $690M | +4% | +75% | 31% | 3.4× | 0.0% | +51.6% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 2.5× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 10.9× | 41.4% | +11.2% |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 0.7× | n/a | n/a |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | n/a | n/a | n/a | n/a |